Group 1 - The core point of the news is the performance and characteristics of Nanjing Pharmaceutical's convertible bonds, which have a current price of 133.129 yuan and a conversion premium rate of 28.64% [1] - Nanjing Pharmaceutical's convertible bonds have a credit rating of "AA+" and a maturity of 6 years, with a coupon rate that increases over the years, starting from 0.20% in the first year to 2.00% in the sixth year [1] - The conversion price for the bonds is set at 5.12 yuan, with the conversion period starting on July 1, 2025 [1] Group 2 - Nanjing Pharmaceutical Co., Ltd. was established in 1951 and is one of the earliest listed companies in China's pharmaceutical distribution industry, currently operating as a regional leader in the sector [2] - The company reported a revenue of 14.2469 billion yuan for the first quarter of 2025, reflecting a year-on-year increase of 2.11%, and a net profit of 177.4 million yuan, which is an increase of 11.49% year-on-year [2] - As of March 2025, the shareholding structure of Nanjing Pharmaceutical is highly dispersed, with the top ten shareholders holding a combined 60.82% of shares and a total of 56,410 shareholders [2]
南药转债盘中下跌2.04%报133.129元/张，成交额1425.92万元，转股溢价率28.64%
Jin Rong Jie·2025-08-27 06:21